Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models.
Latta-Mahieu, Martine
Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models. [electronic resource] - Glia 03 2018 - 492-504 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1098-1136
10.1002/glia.23260 doi
Alzheimer Disease--immunology
Amyloid beta-Peptides--genetics
Animals
Antibodies--administration & dosage
Brain--immunology
Disease Models, Animal
Female
Humans
Immunohistochemistry
Immunotherapy
Interferon-gamma--blood
Male
Mice, Inbred C57BL
Mice, Transgenic
Presenilin-1--genetics
Programmed Cell Death 1 Receptor--immunology
RNA, Messenger--metabolism
Random Allocation
Spleen--immunology
Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-β burden in several amyloid transgenic mouse models. [electronic resource] - Glia 03 2018 - 492-504 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1098-1136
10.1002/glia.23260 doi
Alzheimer Disease--immunology
Amyloid beta-Peptides--genetics
Animals
Antibodies--administration & dosage
Brain--immunology
Disease Models, Animal
Female
Humans
Immunohistochemistry
Immunotherapy
Interferon-gamma--blood
Male
Mice, Inbred C57BL
Mice, Transgenic
Presenilin-1--genetics
Programmed Cell Death 1 Receptor--immunology
RNA, Messenger--metabolism
Random Allocation
Spleen--immunology